KR20140017979A - Vita hybrid tablet for middle aged adult and manufacturing method thereof - Google Patents
Vita hybrid tablet for middle aged adult and manufacturing method thereof Download PDFInfo
- Publication number
- KR20140017979A KR20140017979A KR1020120085121A KR20120085121A KR20140017979A KR 20140017979 A KR20140017979 A KR 20140017979A KR 1020120085121 A KR1020120085121 A KR 1020120085121A KR 20120085121 A KR20120085121 A KR 20120085121A KR 20140017979 A KR20140017979 A KR 20140017979A
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- mixture
- vita
- weight
- coating
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 39
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 37
- 239000011248 coating agent Substances 0.000 claims abstract description 33
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 30
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 22
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 20
- 238000000576 coating method Methods 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 18
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 16
- 239000008101 lactose Substances 0.000 claims abstract description 16
- 229960002477 riboflavin Drugs 0.000 claims abstract description 16
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 15
- 239000001913 cellulose Substances 0.000 claims abstract description 15
- 229920002678 cellulose Polymers 0.000 claims abstract description 15
- 235000010980 cellulose Nutrition 0.000 claims abstract description 15
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 14
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 14
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 14
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 14
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 14
- 239000011719 vitamin A Substances 0.000 claims abstract description 14
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 14
- 239000011709 vitamin E Substances 0.000 claims abstract description 14
- 229940046009 vitamin E Drugs 0.000 claims abstract description 14
- 229940045997 vitamin a Drugs 0.000 claims abstract description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 13
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 13
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 13
- 239000011718 vitamin C Substances 0.000 claims abstract description 13
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 12
- 239000000654 additive Substances 0.000 claims abstract description 12
- 229940099596 manganese sulfate Drugs 0.000 claims abstract description 12
- 239000011702 manganese sulphate Substances 0.000 claims abstract description 12
- 235000007079 manganese sulphate Nutrition 0.000 claims abstract description 12
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims abstract description 12
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 12
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 12
- 238000005303 weighing Methods 0.000 claims abstract description 12
- 239000011787 zinc oxide Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 11
- 239000011812 mixed powder Substances 0.000 claims description 13
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 13
- 235000005282 vitamin D3 Nutrition 0.000 claims description 13
- 239000011647 vitamin D3 Substances 0.000 claims description 13
- 229940021056 vitamin d3 Drugs 0.000 claims description 13
- 241001474374 Blennius Species 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 241000383638 Allium nigrum Species 0.000 claims description 9
- 241000209020 Cornus Species 0.000 claims description 9
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 240000003768 Solanum lycopersicum Species 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 239000006000 Garlic extract Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 235000020706 garlic extract Nutrition 0.000 claims description 8
- 239000000395 magnesium oxide Substances 0.000 claims description 8
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 8
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 8
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940107588 barberry extract Drugs 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 235000012222 talc Nutrition 0.000 claims description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 3
- 244000180278 Copernicia prunifera Species 0.000 claims description 2
- 235000010919 Copernicia prunifera Nutrition 0.000 claims description 2
- 240000000724 Berberis vulgaris Species 0.000 claims 1
- INIZTEMZWOJCAF-UHFFFAOYSA-J dimagnesium octadecanoate Chemical compound [Mg+2].[Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O INIZTEMZWOJCAF-UHFFFAOYSA-J 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 23
- 229940088594 vitamin Drugs 0.000 abstract description 23
- 229930003231 vitamin Natural products 0.000 abstract description 23
- 235000013343 vitamin Nutrition 0.000 abstract description 23
- 239000011782 vitamin Substances 0.000 abstract description 23
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 14
- 235000010755 mineral Nutrition 0.000 abstract description 14
- 239000011707 mineral Substances 0.000 abstract description 14
- 230000003078 antioxidant effect Effects 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 12
- 210000003205 muscle Anatomy 0.000 abstract description 12
- 230000003908 liver function Effects 0.000 abstract description 10
- 210000005036 nerve Anatomy 0.000 abstract description 10
- 230000036039 immunity Effects 0.000 abstract description 9
- 230000004060 metabolic process Effects 0.000 abstract description 9
- 235000015097 nutrients Nutrition 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 6
- 210000002356 skeleton Anatomy 0.000 abstract description 6
- 235000013376 functional food Nutrition 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 4
- 235000015872 dietary supplement Nutrition 0.000 abstract description 3
- 229930003316 Vitamin D Natural products 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 235000019166 vitamin D Nutrition 0.000 abstract 2
- 239000011710 vitamin D Substances 0.000 abstract 2
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 2
- 229940046008 vitamin d Drugs 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 32
- 206010016256 fatigue Diseases 0.000 description 22
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 150000003722 vitamin derivatives Chemical class 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229940096421 milk thistle extract Drugs 0.000 description 6
- 235000020727 milk thistle extract Nutrition 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 241001083847 Berberis Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000002211 L-ascorbic acid Substances 0.000 description 4
- 235000000069 L-ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000037149 energy metabolism Effects 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 235000019192 riboflavin Nutrition 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 240000001439 Opuntia Species 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 241000320380 Silybum Species 0.000 description 2
- 235000010841 Silybum marianum Nutrition 0.000 description 2
- 206010047623 Vitamin C deficiency Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000007177 brain activity Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229910052571 earthenware Inorganic materials 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000006993 memory improvement Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 208000010233 scurvy Diseases 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041052 Sluggishness Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047612 Vitamin B2 deficiency Diseases 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 201000007590 ariboflavinosis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- -1 glycerin fatty acid ester Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 208000004223 riboflavin deficiency Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035938 sexual maturation Effects 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 중장년층을 위한 건강기능식품 및 그 제조 방법에 관한 것으로, 보다 상세하게는 중장년층에게 부족한 영양을 공급해 주고, 피로회복과 면역을 향상시켜 주는 중장년층용 비타 하이브리드 정제 및 그 제조 방법에 관한 것이다.
The present invention relates to a health functional food for the elderly and a method of manufacturing the same, and more particularly to a vita hybrid tablet for the elderly to improve nutrition and improve fatigue and immunity for the elderly, and a method of manufacturing the same.
일반적으로 40대 내지 50대의 중장년층은 사회 활동을 함에 있어서 장시간에 걸친 과도한 업무나 가사일을 하여 과도한 육체적 및 정신적인 스트레스와 피로가 계속 누적되어 건강이 악화되고, 불규칙한 생활 및 식습관으로 인하여 발생한 각종 성인병에 시달리고 있다.In general, middle aged people in their 40s and 50s continue to accumulate excessive physical and mental stress and fatigue due to long periods of excessive work or housework in social activities, resulting in deterioration of health and various adult diseases caused by irregular life and eating habits. I'm suffering.
또한, 중장년층은 신체의 에너지 대사와 활력이 저하되어 신경과 근육 및 골격의 기능이 점차 내리막길을 걷는 시기이고, 누적된 스트레스와 피로로 인하여 간 기능 저하 등의 신체 이상 증상이 나타날 수 있으며, 점차 면역력이 떨어지게 되고, 두뇌 활동도 점차 저하될 수 있다.In addition, the middle-aged people are the period when the energy metabolism and vitality of the body is reduced, the function of nerves, muscles, and skeletons gradually go downhill, and the cumulative stress and fatigue may cause physical abnormalities such as decreased liver function. Immunity is reduced, and brain activity can be gradually reduced.
이러한 중장년층을 위한 종래의 건강기능식품으로서, 대한민국 공개특허공보 제10-2011-0057480호에는 L-아스코르빈산 및 L-아스코르빈산염, 바람직하기는 L-아스코르빈산 및 L-아스코르빈산 나트륨이 1:0.85~2의 중량비로 혼합된 L-아스코르빈산의 혼합물을 직타법으로 가공하여 제조된 비타민 정제에 관하여 개시되어 있다.As a conventional health functional food for the elderly, Korean Laid-Open Patent Publication No. 10-2011-0057480 discloses L-ascorbic acid and L-ascorbic acid salt, preferably L-ascorbic acid and L-ascorbic acid. A vitamin tablet prepared by processing a mixture of L-ascorbic acid in which sodium is mixed in a weight ratio of 1: 0.85 to 2 is disclosed.
그러나, 상기 종래의 기술은 비타민C를 활성성분으로 하여 기호도가 우수하고 씹거나 녹여서 섭취하기에 적합한 제품을 제공할 수는 있으나, 중장년층의 건강에 특히 필요한 여러 가지의 비타민과 미네랄 등을 공급할 수 없고, 이로 인하여 신체의 에너지 대사와 활력이 저하된 중장년층의 신경과 근육 및 골격의 기능 유지에 필요한 영양소를 충분히 보충할 수 없음은 물론, 항산화 기능, 면역력 증진, 간 기능 개선 등에 효과가 없어 중장년층의 건강 유지에 큰 도움이 되지 못하고, 대부분 인공 추출물을 사용하여 체내 흡수율이 낮은 문제가 있었다.
However, the conventional technology can provide a product that is excellent in palatability and suitable for chewing or melting by using vitamin C as an active ingredient, but cannot supply various vitamins and minerals, which are especially necessary for the elderly's health. As a result, they cannot supplement enough nutrients for maintaining the functions of nerves, muscles, and skeletons of the middle-aged people whose energy metabolism and vitality are lowered, and they are not effective in antioxidant function, immunity improvement, and liver function improvement. It was not a great help in the maintenance, and most of the artificial extract was used to have a low absorption rate in the body.
본 발명은 상술한 문제들을 모두 해결하기 위하여 안출된 것으로, 각종 비타민과 미네랄 및 기능성 천연 추출물을 함유한 건강기능식품을 중장년층에게 제공함으로써, 과도한 직장생활로 인하여 받는 스트레스와 피로에 지친 중장년층에게 비타민과 미네랄를 공급하여 신체의 원활한 신진대사와 생리 활성을 유지시켜 주고, 신경과 근육 및 골격의 기능 유지에 필요한 영양소를 보충해 주며, 면역력과 항산화 기능을 증진시킬 뿐만 아니라, 간을 보호하고 간기능을 향상시켜 신체의 피로를 회복시킴으로써 건강하고 활력있는 삶을 유지시켜 주는 중장년층용 비타 하이브리드 정제 및 그 제조 방법의 제공을 그 목적으로 한다.
The present invention has been made to solve all the above problems, by providing a dietary supplement containing various vitamins, minerals and functional natural extracts to the elderly, vitamins and the elderly to tired from stress and fatigue due to excessive work life It supplies minerals to maintain the body's smooth metabolism and physiological activity, replenishes the nutrients needed to maintain nerve, muscle and skeletal function, enhances immunity and antioxidant function, protects the liver and improves liver function. The purpose of the present invention is to provide a vita hybrid tablet for the elderly and a method of manufacturing the same, which maintains a healthy and vital life by restoring the fatigue of the body.
상기 과제를 해결하기 위하여 본 발명은 중량%로, 비타민A 혼합제 0.5 내지 5%, 비타민B1 염산염 0.04 내지 0.4%, 비타민B2 0.03 내지 0.3%, 비타민B6 염산염 0.05 내지 0.5%, 비타민C 5 내지 15%, 비타민D3 혼합제 0.05 내지 0.5%, 비타민E 혼합제 7 내지 17%, 산화아연 0.5 내지 5%, 황산망간 0.1 내지 1%을 포함한 활성성분; 결정셀룰로오스와 유당혼합분말 중에서 선택된 1종 또는 2종이 40 내지 60%를 포함한 부형제; 0.5 내지 5%를 갖는 코팅제; 및 기타 첨가제를 포함하는 중장년층용 비타 하이브리드 정제를 제공한다. In order to solve the above problems, the present invention is a weight%, vitamin A mixture 0.5 to 5%, vitamin B1 hydrochloride 0.04 to 0.4%, vitamin B2 0.03 to 0.3%, vitamin B6 hydrochloride 0.05 to 0.5%, vitamin C 5 to 15% Active ingredients including 0.05-0.5% vitamin D3 admixture, 7-17% vitamin E admixture, 0.5-5% zinc oxide, and 0.1-1% manganese sulfate; Excipients comprising 40 to 60% of one or two selected from crystalline cellulose and lactose mixed powder; Coating agents having 0.5 to 5%; And it provides a vita hybrid tablet for the elderly comprising the other additives.
이때, 상기 활성성분은 헛개나무열매 추출물 1 내지 5%, 밀크씨슬 추출물 0.5 내지 4%, 가시오가피 추출물 0.15 내지 1.5%로 이루어진 군에서 선택된 1종 이상이 더 포함되는 것에도 그 특징이 있다.At this time, the active ingredient is characterized in that it further comprises one or more selected from the group consisting of 1 to 5% of the barberry fruit extract, 0.5 to 4% of milk Thistle extract, 0.15 to 1.5% of the barberry extract.
게다가, 상기 활성성분은 산수유 추출물 0.5 내지 5%, 흑마늘추출물 0.2 내지 2%, 오양자 추출물 0.2 내지 2%로 이루어진 군에서 선택된 1종 이상이 더 포함되는 것에도 그 특징이 있다.In addition, the active ingredient is characterized in that it further comprises at least one selected from the group consisting of cornus extract 0.5 to 5%, black garlic extract 0.2 to 2%, yangyang extract 0.2 to 2%.
뿐만 아니라, 상기 활성성분은 산화마그네슘 0.5 내지 1.5%, 해조 분말 4 내지 12%로 이루어진 군에서 선택된 1종 이상이 더 포함되는 것에도 그 특징이 있다.In addition, the active ingredient is characterized in that it further comprises one or more selected from the group consisting of magnesium oxide 0.5 to 1.5%, seaweed powder 4 to 12%.
나아가, 상기 활성성분은 토마토농축액분말 0.2 내지 2%를 더 포함하는 것에도 그 특징이 있다.Furthermore, the active ingredient is characterized in that it further comprises 0.2 to 2% tomato concentrate powder.
더불어, 상기 부형제는 결정셀룰로오스와 유당혼합분말을 모두 포함하고, 상기 결정셀룰로오스와 유당혼합분말의 혼합비가 중량 기준으로 1:0.5 내지 1:0.7인 것에도 그 특징이 있다.In addition, the excipient includes both crystalline cellulose and lactose mixed powder, and the mixing ratio of the crystalline cellulose and lactose mixed powder is characterized in that 1: 0.5 to 1: 0.7 by weight.
그리고, 상기 코팅제는 히드록시프로필메틸셀룰로오스, 피마자유, 프로필렌글리콜, 폴리에틸렌글리콜, 포비돈, 탈크, 탄산칼슘, 카르나우바납, 이산화규소, 메타아크릴산 공중합체 및 산화티탄으로 이루어진 군에서 선택된 1종 이상으로 이루어지는 것에도 그 특징이 있다.In addition, the coating agent is at least one selected from the group consisting of hydroxypropyl methyl cellulose, castor oil, propylene glycol, polyethylene glycol, povidone, talc, calcium carbonate, carnauba wax, silicon dioxide, methacrylic acid copolymer and titanium oxide It also has its characteristics.
이와 함께, 상기 첨가제는 카르복시메틸셀룰로오스칼슘 0.5 내지 3%, 스테아린산마그네슘 0.5 내지 1.5%를 포함하는 것에도 그 특징이 있다.In addition, the additive is also characterized in that it comprises 0.5 to 3% of carboxymethyl cellulose calcium, 0.5 to 1.5% of magnesium stearate.
또한, 본 발명은 각 원료를 전자저울로 칭량하는 칭량 단계; 중량%로, 비타민A 혼합제 0.5 내지 5%, 비타민B1 염산염 0.04 내지 0.4%, 비타민B2 0.03 내지 0.3%, 비타민B6 염산염 0.05 내지 0.5%, 비타민C 5 내지 15%, 비타민D3 혼합제 0.05 내지 0.5%, 비타민E 혼합제 7 내지 17%, 산화아연 0.5 내지 5%, 황산망간 0.1 내지 1%을 포함한 활성성분과, 결정셀룰로오스와 유당혼합분말 중에서 선택된 1종 또는 2종이 40 내지 60%를 포함한 부형제와, 기타 첨가제를 혼합기에 투입한 후 20 ~ 40분 동안 15 ~ 30 RPM으로 혼합하여 혼합물을 만드는 혼합 단계; 상기 혼합물을 자동 타정기를 이용하여 일정량으로 타정하는 타정 단계; 및 0.5 내지 5%의 코팅제를 주정알콜에 녹여서 코팅기제를 제조한 후 타정된 정제를 코팅기에서 코팅하는 코팅 단계;를 포함하는 중장년층용 비타 하이브리드 정제의 제조 방법을 제공한다.
In addition, the present invention comprises a weighing step of weighing each raw material with an electronic balance; By weight%, Vitamin A admixture 0.5 to 5%, Vitamin B1 hydrochloride 0.04 to 0.4%, Vitamin B2 0.03 to 0.3%, Vitamin B6 hydrochloride 0.05 to 0.5%, Vitamin C 5 to 15%, Vitamin D3 admixture 0.05 to 0.5%, Active ingredients including 7-17% of vitamin E blends, 0.5-5% of zinc oxide, 0.1-1% of manganese sulfate, excipients containing 40-60% of one or two selected from crystalline cellulose and lactose mixed powder, and the like. Adding an additive to the mixer and mixing the mixture at 15 to 30 RPM for 20 to 40 minutes to form a mixture; A tableting step of tableting the mixture in a predetermined amount using an automatic tableting machine; It provides a method for producing a mature hybrid vita hybrid tablet comprising; and a coating step of dissolving 0.5 to 5% of the coating agent in alcohol alcohol to prepare a coating base and then coating the tablet tablet in a coating machine.
본 발명에 의하면, 각종 비타민과 미네랄 및 기능성 천연 추출물을 함유한 건강기능식품을 중장년층에게 제공함으로써, 과도한 직장생활로 인하여 받는 스트레스와 피로에 지친 중장년층에게 비타민과 미네랄를 공급하여 신체의 원활한 신진대사와 생리 활성을 유지시켜 주고, 신경과 근육 및 골격의 기능 유지에 필요한 영양소를 보충해 주며, 면역력과 항산화 기능을 증진시킬 뿐만 아니라, 간을 보호하고 간기능을 향상시켜 신체의 피로를 회복시킴으로써 건강하고 활력있는 삶을 유지시켜 주는 우수한 효과가 있다.
According to the present invention, by providing a health functional food containing various vitamins, minerals and functional natural extracts to the elderly, by supplying vitamins and minerals to the elderly and tired tired from excessive work life, the body's smooth metabolism and physiology It keeps you active, replenishes the nutrients needed to maintain the function of nerves, muscles and skeletons, improves immunity and antioxidant function, protects the liver and improves liver function, thereby restoring fatigue and body health. It has an excellent effect on maintaining a healthy life.
도 1은 본 발명에 따른 중장년층용 비타 하이브리드 정제의 제조 방법의 플로우 차트.1 is a flow chart of the manufacturing method of vita hybrid tablets for the elderly according to the present invention.
본 발명자는 종래의 중장년층을 위한 건강기능식품은 중장년층의 건강에 특히 필요한 여러 가지의 비타민과 미네랄 등을 공급할 수 없고, 이로 인하여 신체의 에너지 대사와 활력이 저하된 중장년층의 신경과 근육 및 골격의 기능 유지에 필요한 영양소를 충분히 보충할 수 없음은 물론, 항산화 기능, 면역력 증진, 간 기능 개선 등에 효과가 없어 중장년층의 건강 유지에 큰 도움이 되지 못하고, 대부분 인공 추출물을 사용하여 체내 흡수율이 낮은 문제가 있음을 인지하고, 이를 해결하기 위하여 연구와 노력을 거듭한 결과, 각종 비타민과 미네랄 및 기능성 천연 추출물을 함유한 건강기능식품을 중장년층에게 제공함으로써, 과도한 직장생활로 인하여 받는 스트레스와 피로에 지친 중장년층에게 비타민과 미네랄를 공급하여 신체의 원활한 신진대사와 생리 활성을 유지시켜 주고, 신경과 근육 및 골격의 기능 유지에 필요한 영양소를 보충해 주며, 면역력과 항산화 기능을 증진시킬 뿐만 아니라, 간을 보호하고 간기능을 향상시켜 신체의 피로를 회복시킴으로써 건강하고 활력있는 삶을 유지시켜 주는 중장년층용 비타 하이브리드 정제 및 그 제조 방법에 관한 본 발명을 완성시켰다.The inventors of the present invention can not supply a variety of vitamins and minerals, etc., which are particularly necessary for the health of the elderly, the function of the nerves, muscles and skeletons of the elderly, the energy metabolism and vitality of the body is lowered Not enough to replenish the nutrients necessary for maintenance, as well as ineffective for antioxidant function, immune system, liver function, etc., it does not help to maintain the health of the middle-aged people, and most artificial extracts have low problem of low absorption As a result of recognizing and resolving this problem, research and efforts have been conducted to provide vitamins and vitamins to seniors who are tired of stress and fatigue due to excessive work life. By supplying minerals and minerals Maintains physiological activity, replenishes the nutrients needed to maintain the function of nerves, muscles and skeletons, improves immunity and antioxidant function, protects the liver and improves liver function to restore body fatigue The present invention relates to a vita hybrid tablet for the elderly and a method for producing the same, which maintains a vital life.
본 발명에 따른 중장년층용 비타 하이브리드 정제는 크게 활성성분, 부형제, 코팅제 및 기타 첨가제를 포함하여 이루어진다.Vita hybrid tablets for the elderly according to the invention largely comprises the active ingredient, excipients, coatings and other additives.
상기 활성성분은 중장년층의 건강과 활력 유지와 스트레스와 피로 회복에 필요한 각종 비타민과 미네랄 및 기능성 천연 추출물을 포함하고 있다.The active ingredient contains various vitamins and minerals and functional natural extracts necessary for maintaining the health and vitality of the elderly and restoring stress and fatigue.
즉, 상기 활성성분은 중량%로, 비타민A 혼합제 0.5 내지 5%, 비타민B1 염산염 0.04 내지 0.4%, 비타민B2 0.03 내지 0.3%, 비타민B6 염산염 0.05 내지 0.5%, 비타민C 5 내지 15%, 비타민D3 혼합제 0.05 내지 0.5%, 비타민E 혼합제 7 내지 17%, 산화아연 0.5 내지 5%, 황산망간 0.1 내지 1%을 포함한다.That is, the active ingredient in weight%, vitamin A mixture 0.5 to 5%, vitamin B1 hydrochloride 0.04 to 0.4%, vitamin B2 0.03 to 0.3%, vitamin B6 hydrochloride 0.05 to 0.5%, vitamin C 5 to 15%, vitamin D3 0.05 to 0.5% of a mixture, 7 to 17% of a vitamin E mixture, 0.5 to 5% of zinc oxide, and 0.1 to 1% of manganese sulfate.
상기 비타민A 혼합제는 비타민A를 주성분으로 함유하고, 그 밖에 말토덱스트린, 옥수수 전분, 아라비아검, 레티닐 아세트산염, DL-알파-토코페롤이 혼합되어 구성된다.The vitamin A admixture contains vitamin A as a main ingredient, in addition to maltodextrin, corn starch, gum arabic, retinyl acetate, DL-alpha-tocopherol is mixed.
상기 비타민A는 지용성 비타민으로서, 신체의 저항력을 강화시키고, 생체막(membrane)의 조직 구조와 기능을 조절하며, 상피세포의 성장인자로서 세포의 재생을 촉진시켜 구강, 기도, 위, 장의 점막을 보호하고, 세포의 산화를 막아주는 항산화제 역할을 하며, 눈의 망막에 있는 간상세포에 존재하는 감광색소인 로돕신(rhodopsin)의 생산에도 관여하여 어두운 곳에서 시각 적응을 위해 필요한 물질로 알려져 있다.The vitamin A is a fat-soluble vitamin, strengthens the body's resistance, regulates the tissue structure and function of the membrane (membrane), and promotes cell regeneration as a growth factor of epithelial cells to protect the mucous membrane of the oral cavity, airway, stomach and intestine In addition, it acts as an antioxidant to prevent the oxidation of cells, and is involved in the production of rhodopsin, a photosensitive pigment present in rod cells in the retina of the eye, and is known as a material necessary for visual adaptation in the dark.
여기서 상기 비타민A 혼합제는 0.5 내지 5 중량%를 함유하는 것이 바람직한 바, 상기 비타민A 혼합제가 0.5 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 비타민A 혼합제가 5 중량%를 초과하면 과량 섭취로 인하여 오히려 피로감, 두통, 설사 및 어지러움 등의 독성 효과가 발생할 수 있기 때문이다.Wherein the vitamin A admixture preferably contains 0.5 to 5% by weight, if the vitamin A admixture is less than 0.5% by weight is insufficient expression of the above-described effect, if the vitamin A admixture exceeds 5% by weight is excessive Ingestion may cause toxic effects such as fatigue, headache, diarrhea and dizziness.
상기 비타민B1 염산염은 C12H17ON4ClS·HCl의 화학식을 갖는 물질로서, 공기 중에서 안정하고, 물에 잘 용해되는 성질을 갖고 있다. The vitamin B1 hydrochloride is a substance having a chemical formula of C 12 H 17 ON 4 ClS.HCl, and is stable in air and has a property of being well soluble in water.
상기 비타민B1은 수용성 비타민에 속하며, 탄수화물과 분지상 아미노산(류신, 이소류신, 발린)의 대사에 필요하고, 에너지 소모량과 상관 관계가 큰 물질로 알려져 있으며, 부족한 경우 초기에는 뚜렷한 증세를 나타내지 않다가 식욕부진, 체중감소, 무감각 등과 같은 정신적 증세, 과민성, 근육 무력증, 심장비대 등의 심혈관계 증세를 수반하며, 심각한 경우 신경계와 심혈관계의 장애를 나타내는 각기병(beriberi)이 유발된다.The vitamin B1 belongs to a water-soluble vitamin, is required for the metabolism of carbohydrates and branched amino acids (leucine, isoleucine, valine), and is known as a substance having a high correlation with energy consumption. It is accompanied by cardiovascular symptoms such as mental symptoms such as sluggishness, weight loss, and numbness, irritability, muscle weakness, and cardiac hypertrophy, and in severe cases, beriberi, which indicates neurological and cardiovascular disorders, is caused.
이때, 상기 비타민B1 염산염은 0.04 내지 0.4 중량%를 함유하는 것이 바람직한 바, 상기 비타민B1 염산염이 0.04 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 비타민B1 염산염이 0.4 중량%를 초과하면 중추 신경계와 관련된 부작용이 발생할 수도 있기 때문이다.At this time, the vitamin B1 hydrochloride preferably contains 0.04 to 0.4% by weight. If the vitamin B1 hydrochloride is less than 0.04% by weight, the expression of the above-mentioned effect is insufficient, and the vitamin B1 hydrochloride exceeds 0.4% by weight. This may be due to side effects associated with the central nervous system.
상기 비타민B2는 리보플라빈이라고도 하고, 수용성 비타민에 속하며, 체내의 에너지 대사에 중요한 물질로서, 리보플라빈 조효소가 여러가지 효소 반응에 관여하고, 다양한 종류의 리보플라빈 효소들이 탄소화물, 지방, 아미노산의 대사 경로에서 탈수소화반응, 수산화반응, 산화탈탄산반응, 이산소화반응, 산소의 과산화수소로의 환원 반응 등에 필수적으로 필요한 물질로 알려져 있다.The vitamin B2, also called riboflavin, belongs to a water-soluble vitamin, and is an important substance for energy metabolism in the body, riboflavin coenzymes are involved in various enzyme reactions, and various kinds of riboflavin enzymes are dehydrogenated in the metabolic pathways of carbohydrates, fats and amino acids. It is known as an essential material for hydroxylation, deoxidation deoxidation, dioxygenation and reduction of oxygen to hydrogen peroxide.
또한, 상기 비타민B2가 결핍될 경우 구강염이 발생하고, 코나 입 주위의 안면이나 음낭, 외음부의 지루성 피부염, 안구충혈이나 조로성 백내장 및 빈혈 등이 발생함은 물론, 신체 활동 중에 쉽게 피곤을 느낀다.In addition, oral inflammation occurs when the vitamin B2 deficiency, facial or scrotum around the nose or mouth, seborrheic dermatitis of the vulva, ocular hyperemia or premature cataracts and anemia, as well as tired easily during physical activity.
이때, 상기 비타민B2는 0.03 내지 0.3 중량%를 함유하는 것이 바람직한 바, 상기 비타민B2가 0.03 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 비타민B2가 0.3 중량%를 초과하면 리보플라빈의 배설량이 증가하여 노란색 소변이 배설될 수 있기 때문이다.At this time, the vitamin B2 is preferably contained 0.03 to 0.3% by weight, the vitamin B2 is less than 0.03% by weight is insufficient expression of the above-described effect, when the vitamin B2 exceeds 0.3% by weight of the amount of riboflavin excreted This increases because yellow urine can be excreted.
상기 비타민B6 염산염은 화학식이 C8H11O3N·HCl로서, 물에 용해되기 쉬운 성질을 갖고 있다.The vitamin B6 hydrochloride has a chemical formula of C 8 H 11 O 3 N · HCl, and is easily soluble in water.
상기 비타민B6는 아미노산과 탄수화물의 대사, 헴합성, 신경전달물질의 합성, 면역 및 지질 대사에 관여하고, 호모시스테인의 이화작용 및 인산화효소 반응의 조효소로 작용하는 물질로 알려져 있으며, 부족시 지루성 피부염, 빈혈, 경련 및 습진 등이 발생한다.The vitamin B6 is involved in the metabolism of amino acids and carbohydrates, heme synthesis, the synthesis of neurotransmitters, immune and lipid metabolism, is known as a substance that acts as a coenzyme of catabolic and kinase reactions of homocysteine, seborrheic dermatitis, Anemia, cramps and eczema occur.
상기 비타민B6 염산염은 0.05 내지 0.5 중량%를 함유하는 것이 바람직한 바, 상기 비타민B6 염산염이 0.05 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 비타민B6 염산염이 0.5 중량%를 초과하면 신경 손상을 유발하여 손발쑤심, 비틀거림 등의 증상이 나타날 수 있기 때문이다.It is preferable that the vitamin B6 hydrochloride contains 0.05 to 0.5% by weight. If the vitamin B6 hydrochloride is less than 0.05% by weight, the expression of the above-mentioned effect is insufficient, and when the vitamin B6 hydrochloride exceeds 0.5% by weight, nerve damage This can cause symptoms such as hand hoofing and staggering.
상기 비타민C는 수용성 비타민에 해당하고 항산화 물질로서 신체를 활성산소로부터 보호하여 암, 동맥경화, 류머티즘 등을 예방하고, 면역체계를 강화시키며, 결합조직과 지지조직의 형성에 가담하여 피부와 잇몸의 건강을 보호해 주고, 기억력 유지와 인지 능력을 향상시켜 주는 물질로 알려져 있다.The vitamin C corresponds to a water-soluble vitamin and as an antioxidant, protects the body from free radicals, prevents cancer, arteriosclerosis, rheumatism, strengthens the immune system, and participates in the formation of connective and supportive tissues. It is known to protect health, maintain memory and improve cognitive ability.
상기 비타민C가 결핍될 경우 콜라겐 합성을 저해하여 괴혈병을 일으켜 잇몸 부종과 출혈 등이 나타나고, 만성 피로, 코피, 소화 장애, 우울증 등이 나타날 수 있으며, 골격 이상이 나타날 수도 있다.When the vitamin C deficiency inhibits collagen synthesis, it causes scurvy, swelling and bleeding of the gums, chronic fatigue, nosebleeds, digestive disorders, depression, and the like, and skeletal abnormalities.
상기 비타민C는 5 내지 15 중량%를 함유하는 것이 바람직한 바, 상기 비타민C가 5 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 비타민C가 15 중량%를 초과하면 철 흡수를 촉진하여 철 과다증이 유발될 수 있고, 속이 쓰리거나 설사를 일으킬 수 있는 문제가 있기 때문이다.The vitamin C is preferably contained 5 to 15% by weight, if the vitamin C is less than 5% by weight the expression of the above-mentioned effect is insufficient, if the vitamin C exceeds 15% by weight to promote iron absorption This can be caused by iron overdose and can cause heartburn or diarrhea.
상기 비타민D3 혼합제는 비타민D3를 함유하고, 그 밖에 아라비아검, 설탕, 옥수수 전분, 글리세린지방산에스테르, DL-알파-토코페롤이 혼합되어 구성된다.The vitamin D3 admixture contains vitamin D3, and is composed of gum arabic, sugar, corn starch, glycerin fatty acid ester, and DL-alpha-tocopherol.
상기 비타민D3는 코레칼시페롤(cholecalciferol)로 불리고, 대구나 다랑어의 간유에 많이 포함된 지용성 비타민으로서, 체내로 유입되어 활성형 비타민으로 변화되고, 칼슘 대사에 중요한 작용을 하며, 담즙산의 도움을 받아 칼슘과 인산염의 흡수를 촉진하여 골격 형성에 도움을 주고, 결핍시 칼슘 결합 단백질의 합성이 불충분하여 골연화증, 골절 등의 문제가 발생할 뿐만 아니라 근육 수축 등의 움직임에 이상이 발생한다.The vitamin D3 is called cholecalciferol, and is a fat-soluble vitamin contained in cod liver oil of cod tuna, which is introduced into the body to change into an active vitamin, plays an important role in calcium metabolism, and helps bile acids. It promotes the absorption of calcium and phosphate to help the formation of the skeleton, and in the absence of insufficient synthesis of calcium-binding protein, as well as problems such as osteomalacia, fractures, as well as abnormal muscle movements.
이때, 상기 비타민D3 혼합제는 0.05 내지 0.5 중량%가 혼합되는 것이 바람직한 바, 상기 비타민D3 혼합제가 0.05 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 비타민D3 혼합제가 0.5 중량%를 초과하면 뼈와 연조직의 석회화, 신장 결석 및 고칼슘혈증 등의 부작용이 발생할 수 있기 때문이다.At this time, the vitamin D3 admixture is preferably 0.05 to 0.5% by weight is mixed, if the vitamin D3 admixture is less than 0.05% by weight is insufficient expression of the above-mentioned effect, if the vitamin D3 admixture exceeds 0.5% by weight This can be due to side effects such as calcification of bones and soft tissues, kidney stones and hypercalcemia.
상기 비타민E 혼합제는 비타민E를 함유하고, 그 밖에 덱스트린, 이산화규소 등이 혼합되어 구성된다.The vitamin E admixture contains vitamin E, and dextrin, silicon dioxide and the like are mixed.
상기 비타민E는 지용성 비타민으로서, 세포막을 유지시키는 역할을 하고, 항산화 물질로서 활성산소를 무력화시키며, 심혈관 질환을 예방하고, 뇌세포의 손상을 방지하여 알츠하이머병의 진행을 억제하며, 결핍시 쉽게 세포의 손상을 가져오고, 적혈구의 용혈현상과 근육과 신경 세포가 손상될 수 있으며, 생식 불능, 근위축증, 신경질환 및 빈혈 등의 발생한다.The vitamin E is a fat-soluble vitamin, serves to maintain cell membranes, neutralizes free radicals as antioxidants, prevents cardiovascular disease, prevents damage to brain cells, inhibits the progression of Alzheimer's disease, and easily depletes cells when deficient. It can cause damage, hemolysis of red blood cells and muscle and nerve cells can be damaged, infertility, muscular dystrophy, neurological diseases and anemia.
상기 비타민E 혼합제는 7 내지 17 중량%를 혼합하는 것이 바람직한 바, 상기 비타민E 혼합제가 7 중량% 미만이면 상술한 효과의 발현이 부족하게 되고, 상기 비타민E 혼합제가 17 중량%를 초과하면 비타민K의 흡수를 방해하여 혈소판 응집의 감소, 위장 장애, 근육 약화, 두통 및 만성 피로 등의 증상이 나타날 수 있기 때문이다. The vitamin E admixture is preferably mixed 7 to 17% by weight. If the vitamin E admixture is less than 7% by weight, the expression of the above-mentioned effect is insufficient, and the vitamin E admixture exceeds 17% by weight of vitamin K It can interfere with the absorption of the platelets, reducing the platelet aggregation, gastrointestinal disorders, muscle weakness, headache and chronic fatigue.
상기 산화아연은 산소와 아연의 화합물로서 가벼운 백색 분말이며, 아연화라고도 불리는 물질로서, 신체의 정상적인 면역 기능과 세포 분열에 관여한다.The zinc oxide is a light white powder as a compound of oxygen and zinc and is also called zincation and is involved in the body's normal immune function and cell division.
아연이 결핍될 경우 면역 기능이 약화되어 감염이 쉽게 발생하고, 성장 장애 및 성적 성숙 지연 등의 현상이 발생할 수 있다.Zinc deficiency can weaken immune function and lead to infections, growth disorders and delayed sexual maturation.
상기 산화아연은 0.5 내지 5 중량%를 함유하는 것이 바람직하고, 상기 산화아연이 0.5 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 산화아연이 5 중량%를 초과하면 위점막을 자극하고, 구토, 설사 및 식욕부진 등의 부작용이 발생할 수 있기 때문이다.The zinc oxide preferably contains 0.5 to 5% by weight, when the zinc oxide is less than 0.5% by weight, the expression of the above-mentioned effect is insufficient, and when the zinc oxide is more than 5% by weight, the gastric mucosa is stimulated. May cause side effects such as vomiting, diarrhea and anorexia.
상기 황산망간은 망간의 황산염으로서 무색의 조해성 고체이고, 화학식은 MnSO4이며, 물에 용해되는 물질로서, 뼈와 골격의 형성에 관여하고, 에너지의 이용에 필요하며, 유해산소로부터 세포를 보호하는 기능을 한다.The manganese sulfate is a colorless deliquescent solid as a sulfate of manganese, and the chemical formula is MnSO 4 , a substance soluble in water, involved in the formation of bone and skeleton, necessary for the use of energy, and protecting cells from harmful oxygen. Function
망간이 결핍될 경우 신체의 성장이 지연되고, 생식기능이 저하되며, 탄수화물과 지질의 대사에 변화를 초래하고, 특히 골격 발달을 저해한다.Lack of manganese delays the growth of the body, impairs reproductive function, alters the metabolism of carbohydrates and lipids, and in particular inhibits skeletal development.
상기 황산망간은 0.1 내지 1 중량%를 함유하는 것이 바람직하고, 상기 황산망간이 0.1 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 황산망간이 1 중량%를 초과하면 근육통, 피로, 떨림, 반사 능력 감소 등 신경 독성 증세가 나타날 수 있기 때문이다. The manganese sulfate preferably contains 0.1 to 1% by weight, the manganese sulfate is less than 0.1% by weight, the expression of the above-mentioned effect is insufficient, when the manganese sulfate exceeds 1% by weight myalgia, fatigue, tremor This may be due to neurotoxic symptoms such as decreased reflexes.
여기서, 상기 활성성분은 헛개나무열매 추출물 1 내지 5%, 밀크씨슬 추출물 0.5 내지 4%, 가시오가피 추출물 0.15 내지 1.5%로 이루어진 군에서 선택된 1종 이상이 더 포함될 수 있다.Here, the active ingredient may further include one or more selected from the group consisting of 1 to 5% of the fruit tree extract, 0.5 to 4% of milk Thistle extract, 0.15 to 1.5% of the barberry extract.
상기 헛개나무열매 추출물은 헛개나무의 열매로부터 통상의 추출방법에 의하여 추출한 물질로서, 알코올을 해독하여 간을 보호하고, 간기능의 개선에 도움을 주며, 피로 회복과 변비 예방에도 효능이 있는 것으로 알려져 있다.The barberry fruit extract is a material extracted by the usual extraction method from the fruit of the bark tree, detoxify the alcohol to protect the liver, help improve liver function, is known to be effective in the recovery of fatigue and prevention of constipation have.
상기 헛개나무열매 추출물은 1 내지 5 중량%를 함유하는 것이 바람직한 바, 상기 헛개나무열매 추출물이 1 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 헛개나무열매 추출물이 5 중량%를 초과하면 피부 발진 등의 부작용이 발생할 수 있기 때문이다.The barberry fruit extract preferably contains 1 to 5% by weight, if the barberry fruit extract is less than 1% by weight, the expression of the above-mentioned effect is insufficient, and the barberry fruit extract is more than 5% by weight. This can cause side effects, such as skin rashes.
상기 밀크씨슬(milk thistle) 추출물은 마리아엉겅퀴로부터 통상의 추출방법에 의하여 추출한 물질로서, 실리마린(silymarin)을 함유하여 간세포의 신진대사를 증진시키고, 알코올 등의 독성으로부터 간세포를 보호하며, 지방간, 간경화를 개선하는 효능이 있는 것으로 알려져 있다.The milk thistle (milk thistle) extract is a material extracted from the Maria thistle by a conventional extraction method, contains silymarin (silymarin) to enhance the metabolism of liver cells, protect liver cells from the toxicity of alcohol, fatty liver, It is known to have the effect of improving cirrhosis.
상기 밀크씨슬 추출물은 0.5 내지 4 중량%를 함유하는 것이 바람직한 바, 상기 밀크씨슬 추출물이 0.5 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 밀크씨슬 추출물이 4 중량%를 초과하면 설사나 담즙의 과다 분비 등의 부작용이 나타날 수 있기 때문이다.The milk thistle extract is preferably contained 0.5 to 4% by weight, if the milk thistle extract is less than 0.5% by weight the expression of the above-mentioned effect is insufficient, the milk thistle extract is more than 4% by weight This can cause side effects such as diarrhea and excess bile secretion.
상기 가시오가피 추출물은 가시오가피 식물로부터 통상의 추출방법에 의하여 추출한 물질로서, 신체기관의 전반적인 기능을 증대시켜 주고, 간 기능을 회복시켜 스트레스와 피로를 풀어주는 효과가 있는 것으로 알려져 있다.The prickly pear extract is a material extracted by a common extraction method from prickly pear plants, and is known to have an effect of increasing the overall function of body organs and restoring liver function to relieve stress and fatigue.
여기서, 상기 가시오가피 추출물은 0.15 내지 1.5 중량%를 포함하는 것이 바람직한 바, 상기 가시오가피 추출물이 0.15 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 가시오가피 추출물이 1.5 중량%를 초과하면 다른 성분과의 균형이 깨지고 제조 원가가 상승하기 때문이다.Here, it is preferable that the barb extract contains 0.15 to 1.5% by weight. If the barb extract is less than 0.15% by weight, the expression of the above-mentioned effect is insufficient, and when the barb extract exceeds 1.5% by weight, This is because the balance is broken and manufacturing costs rise.
더불어, 상기 활성성분은 산수유 추출물 0.5 내지 5 중량%, 흑마늘 추출물 0.2 내지 2 중량%, 오양자 추출물 0.2 내지 2 중량%로 이루어진 군에서 선택된 1종 이상이 더 포함될 수 있다.In addition, the active ingredient may be further included one or more selected from the group consisting of cornus extract 0.5 to 5% by weight, black garlic extract 0.2 to 2% by weight, yangyang extract 0.2 to 2% by weight.
상기 산수유 추출물은 산수유 열매로부터 통상의 추출방법에 의하여 추출한 물질로서, 자양강장, 항산화 작용, 피로 회복에 효능이 있고, 신장의 생리 기능을 강화하고 정력을 증진시켜 주는 것으로 잘 알려져 있다.The cornus extract is a substance extracted by the usual extraction method from the cornus fruit, it is well known to be effective in nourishing tonic, antioxidant action, fatigue recovery, enhance the physiological function of the kidneys and enhance the energy.
이때, 상기 산수유 추출물은 0.5 내지 5 중량%를 포함하는 것이 바람직한 바, 상기 산수유 추출물이 0.5 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 산수유 추출물이 5 중량%를 초과하면 체질에 맞지 않는 사람에게 부작용이 나타날 수 있기 때문이다.At this time, the cornus extract preferably contains 0.5 to 5% by weight, if the cornus extract is less than 0.5% by weight, the expression of the above-mentioned effect is insufficient, and if the cornus extract exceeds 5% by weight, it does not fit the constitution. This is because it can cause side effects in people who do not.
상기 흑마늘 추출물은 흑마늘로부터 통상의 추출방법에 의하여 추출한 물질로서, 스트레스와 피로를 회복시켜 주고, 해독 작용을 하며, 두뇌 활동을 도와 치매를 예방하고, 각종 성인병 예방에 효능이 있는 것으로 알려져 있다.The black garlic extract is a material extracted by the usual extraction method from black garlic, it is known to be effective in restoring stress and fatigue, detoxifying action, help brain activity to prevent dementia, and prevent various adult diseases.
여기서, 상기 흑마늘 추출물은 0.2 내지 2 중량%를 함유하는 것이 바람직한 바, 상기 흑마늘 추출물이 0.2 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 흑마늘 추출물이 2 중량%를 초과하면 위점막이 손상될 수 있는 부작용이 있기 때문이다.Here, the black garlic extract preferably contains 0.2 to 2% by weight, if the black garlic extract is less than 0.2% by weight, the expression of the above-mentioned effect is insufficient, and if the black garlic extract exceeds 2% by weight, the gastric mucosa This is because there are side effects that can be damaged.
상기 오양자 추출물은 오미자, 구기자, 복분자, 사상자 및 토사자 등의 오양자 식물들로부터 통상의 추출방법에 의하여 추출한 물질로서, 원기를 회복시키고 신체의 활력을 증강시키며, 혈액순환을 개선하고, 폴리페놀을 함유하여 항산화 작용을 증진시킨다.The yangja extract is a material extracted by conventional extraction methods from yangja plants such as Schisandra chinensis, gojijaja, bokbunja, casualties and earthenware, restores energy, enhances the vitality of the body, improves blood circulation, polyphenols Promotes antioxidant activity by containing
이때, 상기 오양자 추출물은 오미자, 구기자, 복분자, 사상자 및 토사자가 각각 동일한 중량비로 포함된 오양자 고형분 30%와, 덱스트린 70%를 배합하여 이루어진다.At this time, the quinilla extract is made by mixing 30% yangyang solid content and dextrin 70% each containing Schisandra chinensis, wolfberry, bokbunja, casualties and earthenware in the same weight ratio.
상기 오양자 추출물은 0.2 내지 2 중량%를 포함하는 것이 바람직한 바, 상기 오양자 추출물이 0.2 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 오양자 추출물이 2 중량%를 초과하면 다른 성분하고의 균형이 깨지고 제조 원가가 상승하기 때문이다.It is preferable that the quantum extract contains 0.2 to 2% by weight. If the quantum extract is less than 0.2% by weight, the expression of the above-mentioned effect is insufficient, and when the quantum extract exceeds 2% by weight, the other components This is because the balance of labor costs is broken and manufacturing costs rise.
나아가, 상기 활성성분은 산화마그네슘 0.5 내지 1.5 중량%, 해조 분말 4 내지 12 중량%로 이루어진 군에서 선택된 1종 이상이 더 포함될 수 있다.Furthermore, the active ingredient may further include one or more selected from the group consisting of magnesium oxide 0.5 to 1.5% by weight, seaweed powder 4 to 12% by weight.
상기 산화마그네슘은 신경과 근육 기능을 유지하고, 튼튼한 골격을 유지하게 해 주며, 에너지의 생성과 체온 및 혈압 조절 등 생리 작용에 관여하며, 결핍시 정신장애, 망상, 불안, 신경과민, 흥분, 집중력 장애, 우울증 및 불면증 등의 증상이 나타날 수 있다.The magnesium oxide maintains nerve and muscle function, maintains a strong skeleton, is involved in the production of energy and physiological activities such as temperature and blood pressure control, mental deficiency, delusion, anxiety, nervousness, excitement, concentration when deficient Symptoms may include disability, depression and insomnia.
상기 산화마그네슘은 0.5 내지 1.5 중량%를 함유하는 것이 바람직한 바, 상기 산화마그네슘이 0.5 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 산화마그네슘이 1.5 중량%를 초과하면 호흡이 느려지고, 혼수, 혼돈, 환각, 구토, 식욕부진 등의 부작용이 나타날 수 있기 때문이다.The magnesium oxide preferably contains 0.5 to 1.5% by weight. If the magnesium oxide is less than 0.5% by weight, the expression of the above-described effects is insufficient, and when the magnesium oxide is more than 1.5% by weight, respiration is slowed and coma May cause side effects such as confusion, hallucinations, vomiting and loss of appetite.
상기 해조 분말은 미역, 김, 다시다 등의 해조류를 갈아서 만든 분말로서, 뼈와 치아의 형성 및 유지에 관여하고, 신경과 근육의 기능 유지 작용을 하며, 콜레스테롤의 수치와 혈압을 내리는 것으로 알려져 있다. The seaweed powder is a powder made by grinding seaweed such as seaweed, seaweed, and seaweed, is involved in the formation and maintenance of bones and teeth, maintains the function of nerves and muscles, and lowers cholesterol levels and blood pressure.
상기 해조 분말은 4 내지 12 중량%를 함유하는 것이 바람직한 바, 상기 해조 분말이 4 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 해조 분말이 12 중량%를 초과하면 다른 성분과의 균형이 깨지고 제조 원가가 상승하기 때문이다.It is preferable that the seaweed powder contains 4 to 12% by weight. If the seaweed powder is less than 4% by weight, the expression of the above-described effects will be insufficient, and if the seaweed powder exceeds 12% by weight, it will be balanced with other ingredients. This breaks down and manufacturing costs rise.
아울러, 상기 활성성분은 토마토농축액분말 0.2 내지 2 중량%를 더 포함할 수 있다.In addition, the active ingredient may further comprise 0.2 to 2% by weight of tomato concentrate powder.
상기 토마토농축액분말은 토마토농축액을 분말화한 것으로, 각종 비타민이 풍부하게 함유되어 항산화 및 항암 효과가 우수하고, 면역력을 증진시키며, 동맥경화를 예방해 주고, 신진대사를 촉진시켜 피로를 회복시켜 주는 효능이 있는 것으로 알려져 있다.The tomato concentrate powder is a powder of tomato concentrate, which is rich in various vitamins, which have excellent antioxidant and anticancer effects, enhance immunity, prevent arteriosclerosis, and promote metabolism to restore fatigue. It is known that this is.
상기 토마토농축액분말은 0.2 내지 2 중량%를 포함하는 것이 바람직한 바, 상기 토마토농축액분말이 0.2 중량% 미만이면 상술된 효과의 발현이 부족하게 되고, 상기 토마토농축액분말이 2 중량%를 초과하면 위장이 약한 사람이나 냉증이 있는 사람에게는 좋지 않기 때문이다.It is preferable that the tomato concentrate powder contains 0.2 to 2% by weight. If the tomato concentrate powder is less than 0.2% by weight, the expression of the above-mentioned effect is insufficient, and when the tomato concentrate powder exceeds 2% by weight, the stomach may be It is not good for those who are weak or have coldness.
상기 부형제로서, 결정셀룰로오스와 유당혼합분말 중에서 선택된 1종 또는 2종이 40 내지 60 중량%를 포함한다.As the excipient, one or two selected from crystalline cellulose and lactose mixed powder contains 40 to 60% by weight.
상기 결정셀룰로오스는 알약이나 캡슐의 형태를 이루기 위해 사용되는 첨가제로서, α-셀룰로오스를 무기산에 의해 부분적으로 해중합하여 정제한 것이고, 비섬유상 부분으로 구성되어 있으며, 유동성을 갖고 있다.The crystalline cellulose is an additive used to form a pill or capsule. The crystalline cellulose is partially depolymerized and purified by α-cellulose with an inorganic acid, is composed of a non-fibrous portion, and has fluidity.
상기 유당혼합분말은 유당 95 중량%와 덱스트린 5 중량%를 배합하여 제조된 분말로서, 알약이나 캡슐의 형태를 만드는데 사용된다.The lactose mixed powder is a powder prepared by mixing 95% by weight of lactose and 5% by weight of dextrin, and is used to form pills or capsules.
이때, 상기 부형제가 결정셀룰로오스와 유당혼합분말을 모두 포함하는 경우, 상기 결정셀룰로오스와 유당혼합분말의 혼합비가 중량 기준으로 1:0.5 내지 1:0.7인 것이 바람직하고, 더욱 바람직하게는 1:0.65인 것이 좋다. 이는 정제로의 압축 성형의 용이성과, 복용의 편의성을 고려한 것이다.In this case, when the excipient includes both crystalline cellulose and lactose mixed powder, the mixing ratio of the crystalline cellulose and lactose mixed powder is preferably 1: 0.5 to 1: 0.7 by weight, more preferably 1: 0.65. It is good. This takes into account the ease of compression molding into tablets and the convenience of taking.
상기 코팅제는 상기 활성성분이 열과 수분에 불안정하므로, 상기 활성성분과 부형제 등이 혼합되어 제조된 정제는 적절한 코팅제를 이용하여 외부에 코팅층을 형성함으로써 장시간의 경시 변화에도 안정성을 유지할 수 있다.Since the coating agent is unstable in heat and moisture, the tablet prepared by mixing the active ingredient and excipients can maintain stability even with a long time change by forming a coating layer on the outside using an appropriate coating agent.
이때, 상기 코팅제의 함량은 0.5 내지 5 중량%를 갖도록 하는 것이 바람직한데, 상기 코팅제의 함량이 0.5 중량% 미만이면 정제의 안정성을 충분히 확보할 수 없고, 상기 코팅제의 함량이 5 중량%를 초과하면 정제의 적절한 붕해 및 활성성분의 방출을 방해할 수 있기 때문이다.At this time, it is preferable that the content of the coating agent is 0.5 to 5% by weight. When the content of the coating agent is less than 0.5% by weight, the stability of the tablet cannot be sufficiently secured, and when the content of the coating agent is more than 5% by weight. As it may interfere with proper disintegration of the tablet and release of the active ingredient.
여기서, 상기 코팅제는 히드록시프로필메틸셀룰로오스, 피마자유, 프로필렌글리콜, 폴리에틸렌글리콜, 포비돈, 탈크, 탄산칼슘, 카르나우바납, 이산화규소, 메타아크릴산 공중합체 및 산화티탄으로 이루어진 군에서 선택된 1종 이상으로 이루어질 수 있다.Here, the coating agent is at least one selected from the group consisting of hydroxypropyl methyl cellulose, castor oil, propylene glycol, polyethylene glycol, povidone, talc, calcium carbonate, carnauba lead, silicon dioxide, methacrylic acid copolymer and titanium oxide Can be done.
상기 첨가제는 카르복시메틸셀룰로오스칼슘 0.5 내지 3%, 스테아린산마그네슘 0.5 내지 1.5%를 포함한다. 상기 카르복시메틸셀룰로오스칼슘 및 스테아린산마그네슘은 정제의 점착성 및 점도를 증가시키고 유화안정성을 증진시키며, 정제의 물성을 향상시키기 위하여 첨가한다.The additives include 0.5 to 3% of carboxymethyl cellulose calcium and 0.5 to 1.5% of magnesium stearate. The carboxymethyl cellulose calcium and magnesium stearate are added to increase the adhesiveness and viscosity of the tablet, to improve the emulsion stability, and to improve the physical properties of the tablet.
도 1에 도시된 바와 같이, 본 발명에 따른 중장년층용 비타 하이브리드 정제의 제조 방법은 먼저 각 원료를 전자저울로 칭량하는 칭량 단계(S10 단계)를 수행한다.As shown in Figure 1, the method for producing a vana hybrid tablet for the elderly according to the present invention first performs a weighing step (step S10) for weighing each raw material with an electronic balance.
상기 칭량 단계(S10 단계)는 규격 기준에 적합한 각 원료를 확인 구입한 후 품질 검사를 하며, 품질 검사가 끝난 각 원료를 미생물의 혼입 우려가 없는 원료칭량실에서 사용되는 양만큼 전자저울로 칭량한다.The weighing step (S10 step) checks and purchases each raw material conforming to the standard standards, and performs a quality inspection, and weighs each of the finished raw materials into electronic balances by the amount used in the raw material weighing chamber without fear of microbial incorporation. .
상기 칭량 단계(S10 단계)의 수행 후, 중량%로, 비타민A 혼합제 0.5 내지 5%, 비타민B1 염산염 0.04 내지 0.4%, 비타민B2 0.03 내지 0.3%, 비타민B6 염산염 0.05 내지 0.5%, 비타민C 5 내지 15%, 비타민D3 혼합제 0.05 내지 0.5%, 비타민E 혼합제 7 내지 17%, 산화아연 0.5 내지 5%, 황산망간 0.1 내지 1%을 포함한 활성성분과, 결정셀룰로오스와 유당혼합분말 중에서 선택된 1종 또는 2종이 40 내지 60%를 포함한 부형제와, 기타 첨가제를 혼합기에 투입한 후 20 ~ 40분 동안 15 ~ 30 RPM으로 혼합하여 혼합물을 만드는 혼합 단계(S20 단계)를 수행한다.After performing the weighing step (step S10), in weight percent, 0.5 to 5% of vitamin A admixture, 0.04 to 0.4% of vitamin B1 hydrochloride, 0.03 to 0.3% of vitamin B2, 0.05 to 0.5% of vitamin B6 hydrochloride, and 5 to 5% of vitamin C. 15%, 0.05-0.5% of vitamin D3 mixture, 7-17% of vitamin E mixture, 0.5-5% of zinc oxide, 0.1-1% of manganese sulfate, and one or two selected from crystalline cellulose and lactose mixed powder An excipient including 40 to 60% of paper and other additives are added to the mixer, followed by mixing at 15 to 30 RPM for 20 to 40 minutes to form a mixture (step S20).
상기 혼합 단계(S20 단계)는 혼합 시간이 너무 짧거나 혼합속도가 낮으면 잘 혼합되지 않거나 혼합물의 점도가 낮아 후속 공정에 지장을 주고, 혼합 시간이 너무 길거나 혼합속도가 높으면 혼합 효과가 포화되므로, 혼합기에 투입한 후 20 ~ 40분 동안 15 ~ 30 RPM으로 혼합하여 혼합물을 만드는 것이 바람직하다.If the mixing step (S20 step) is too short or the mixing speed is not mixed well or the viscosity of the mixture is hindered in the subsequent process, if the mixing time is too long or the mixing speed is high, the mixing effect is saturated, It is preferable to make a mixture by mixing at 15 to 30 RPM for 20 to 40 minutes after adding to the mixer.
상기 혼합 단계(S20 단계)의 수행 후, 상기 혼합물을 자동 타정기를 이용하여 일정량으로 타정하는 타정 단계(S30 단계)를 수행한다.After performing the mixing step (step S20), the tableting step (S30 step) to tablet the mixture in a predetermined amount using an automatic tableting machine.
그리고, 상기 타정 단계(S30 단계)의 수행 후, 0.5 내지 5%의 코팅제를 주정알콜에 녹여서 코팅기제를 제조한 후 타정된 정제를 코팅기에서 코팅하는 코팅 단계(S40 단계)를 수행하여 본 발명에 따른 중장년층용 비타 하이브리드 정제를 제조하는 것이다.
Then, after performing the tableting step (step S30), 0.5 to 5% of the coating agent is dissolved in alcohol alcohol to prepare a coating base, and then performing a coating step (S40 step) to coat the tablets on the coating machine in the present invention. It is to prepare a vita hybrid tablet for the elderly.
[[ 실시예Example ]]
하기의 표 1에 기재된 각 원료 및 함량을 원료칭량실에서 전자저울로 칭량하고, 코팅제인 히드록시프로필메틸셀룰로오스 1.5 중량%를 제외한 나머지 칭량한 원료들을 혼합기에 투입하여 25분간 22rpm으로 혼합하여 혼합물을 생성하며, 생성된 혼합물을 자동타정기로 1정에 591mg씩 되도록 타정하였다.The raw materials and contents shown in Table 1 below were weighed with an electronic balance in a raw material weighing chamber, and the remaining raw materials except 1.5 wt% of hydroxypropylmethylcellulose as a coating agent were added to a mixer and mixed at 22 rpm for 25 minutes to mix the mixture. It was produced, and the resulting mixture was compressed into tablets 591mg per tablet with a tableting machine.
다음에, 1.5 중량%의 히드록시프로필메틸셀룰로오스를 주정알콜에 녹여서 코팅기제를 제조한 후 타정된 정제를 코팅기에서 코팅하여 1정에 600mg을 갖는 코팅된 정제를 제조하였다.
Next, 1.5 wt% of hydroxypropylmethylcellulose was dissolved in alcoholic alcohol to prepare a coating base, and the tableted tablets were coated on a coating machine to prepare coated tablets having 600 mg per tablet.
[표 1][Table 1]
그리고, 실시예 1 내지 5에서 제조된 본 발명에 따른 중장년층용 비타 하이브리드 정제의 스트레스 회복도, 피로 회복도, 근육 및 골격 기능의 향상된 느낌, 기억력 향상도 등에 대하여 시험조사를 실시하였고, 그 결과를 평균하여 아래의 표 2에 나타내었다.In addition, a test investigation was performed on the stress recovery, fatigue recovery, improved feeling of muscle and skeletal function, memory improvement, etc. of the vita hybrid tablets for the elderly according to the present invention prepared in Examples 1 to 5, and the results The average is shown in Table 2 below.
상기 시험조사는 40인의 50대 중장년층에게 상기 실시예1 내지 5에 의해 제조된 중장년층용 비타 하이브리드 정제를 1달(30일) 동안 매일 1회 1정씩 물과 함께 섭취하게 한 후 1달(30일) 뒤에 시험조사를 실시하였다.
The test was conducted after 40 people aged in their 50's to take the vita hybrid tablets for the elderly aged 1 to 5 once daily for 1 month (30 days) 1 month (30 days) The test was carried out.
[표 2][Table 2]
☞ 10점 : 매우 좋다, 5점 : 보통이다, 1점 : 매우 나쁘다
☞ 10 points: Very good, 5 points: Normal, 1 point: Very bad
상기 표 2에 나타난 바와 같이, 실시예 1 내지 5 모두 스트레스 회복도, 피로 회복도, 근육 및 골격 기능의 향상 및 기억력 향상도가 우수한 것으로 확인되었고, 특히, 활성성분으로 비타민과 미네랄을 비롯하여 헛개나무열매 추출물, 밀크씨슬 추출물, 가시오가피 추출물, 산수유 추출물, 흑마늘 추출물, 오양자 추출물, 산화마그네슘, 해조 분말 및 토마토농축액분말 등이 함께 함유된 실시예 5에 대한 평가가 가장 우수하였다.As shown in Table 2, Examples 1 to 5 were found to be excellent in both stress recovery, fatigue recovery, muscle and skeletal function improvement and memory improvement, in particular, the active ingredient, including hawthorn and vitamins and minerals Evaluation of Example 5 containing fruit extract, milk thistle extract, prickly pear extract, cornus extract, black garlic extract, quinoa extract, magnesium oxide, seaweed powder and tomato concentrate powder was the best evaluation.
따라서, 본 발명에 따라 제조된 중장년층용 비타 하이브리드 정제는 각종 비타민과 미네랄 및 기능성 천연 추출물을 함유한 건강기능식품을 중장년층에게 제공함으로써, 과도한 직장생활로 인하여 받는 스트레스와 피로에 지친 중장년층에게 비타민과 미네랄를 공급하여 신체의 원활한 신진대사와 생리 활성을 유지시켜 주고, 신경과 근육 및 골격의 기능 유지에 필요한 영양소를 보충해 주며, 면역력과 항산화 기능을 증진시킬 뿐만 아니라, 간을 보호하고 간기능을 향상시켜 신체의 피로를 회복시킴으로써 건강하고 활력있는 삶을 유지시켜 줄 수 있는 것임을 확인할 수 있었다.Therefore, the vita hybrid tablets for the elderly prepared according to the present invention by providing a health functional food containing various vitamins, minerals and functional natural extracts to the elderly, vitamins and minerals to the elderly aged tired from stress and fatigue due to excessive work life Supplying to maintain smooth metabolism and physiological activity of the body, replenishing the nutrients necessary to maintain the function of nerves, muscles and skeletal function, improve immunity and antioxidant function, protect liver and improve liver function Restoring the fatigue of the body was able to confirm that it can maintain a healthy and vital life.
본 발명에서 상기 실시 형태는 하나의 예시로서 본 발명이 여기에 한정되는 것은 아니다. 본 발명의 특허청구범위에 기재된 기술적 사상과 실질적으로 동일한 구성을 갖고 동일한 작용효과를 이루는 것은 어떠한 것이라도 본 발명의 기술적 범위에 포함된다.
The present invention is not limited to the above-described embodiments. Anything having substantially the same constitution as the technical idea described in the claims of the present invention and achieving the same operational effect is included in the technical scope of the present invention.
Claims (9)
비타민A 혼합제 0.5 내지 5%, 비타민B1 염산염 0.04 내지 0.4%, 비타민B2 0.03 내지 0.3%, 비타민B6 염산염 0.05 내지 0.5%, 비타민C 5 내지 15%, 비타민D3 혼합제 0.05 내지 0.5%, 비타민E 혼합제 7 내지 17%, 산화아연 0.5 내지 5%, 황산망간 0.1 내지 1%을 포함한 활성성분;
결정셀룰로오스와 유당혼합분말 중에서 선택된 1종 또는 2종이 40 내지 60%를 포함한 부형제;
0.5 내지 5%를 갖는 코팅제; 및 기타 첨가제를 포함하는 중장년층용 비타 하이브리드 정제.
By weight,
Vitamin A Blend 0.5 to 5%, Vitamin B1 Hydrochloride 0.04 to 0.4%, Vitamin B2 0.03 to 0.3%, Vitamin B6 Hydrochloride 0.05 to 0.5%, Vitamin C 5 to 15%, Vitamin D3 Blend 0.05 to 0.5%, Vitamin E Blend 7 To 17%, 0.5 to 5% zinc oxide, 0.1 to 1% manganese sulfate;
Excipients comprising 40 to 60% of one or two selected from crystalline cellulose and lactose mixed powder;
Coating agents having 0.5 to 5%; And vita hybrid tablets for the elderly, including other additives.
상기 활성성분은 헛개나무열매 추출물 1 내지 5%, 밀크씨슬 추출물 0.5 내지 4%, 가시오가피 추출물 0.15 내지 1.5%로 이루어진 군에서 선택된 1종 이상이 더 포함되는 중장년층용 비타 하이브리드 정제.
The method of claim 1,
The active ingredient is a vita hybrid tablet for the elderly, which further comprises one or more selected from the group consisting of 1 to 5% of the barberry fruit extract, 0.5 to 4% milk extract, 0.15 to 1.5% barberry extract.
상기 활성성분은 산수유 추출물 0.5 내지 5%, 흑마늘 추출물 0.2 내지 2%, 오양자 추출물 0.2 내지 2%로 이루어진 군에서 선택된 1종 이상이 더 포함되는 중장년층용 비타 하이브리드 정제.
The method of claim 1,
The active ingredient is a vita hybrid tablet for middle aged layer further comprises at least one selected from the group consisting of cornus extract 0.5 to 5%, black garlic extract 0.2 to 2%, yangyang extract 0.2 to 2%.
상기 활성성분은 산화마그네슘 0.5 내지 1.5%, 해조 분말 4 내지 12%로 이루어진 군에서 선택된 1종 이상이 더 포함되는 중장년층용 비타 하이브리드 정제.
The method of claim 1,
Wherein the active ingredient is 0.5 to 1.5% magnesium oxide, 4 to 12% seaweed powder Vita hybrid tablets for the elderly further comprises at least one selected from the group consisting of.
상기 활성성분은 토마토농축액분말 0.2 내지 2%를 더 포함하는 중장년층용 비타 하이브리드 정제.
The method of claim 1,
The active ingredient vita hybrid tablets for the elderly, further comprising 0.2 to 2% tomato concentrate powder.
상기 부형제는 결정셀룰로오스와 유당혼합분말을 모두 포함하고,
상기 결정셀룰로오스와 유당혼합분말의 혼합비가 중량 기준으로 1:0.5 내지 1:0.7인 것을 특징으로 하는 중장년층용 비타 하이브리드 정제.
The method of claim 1,
The excipient includes both crystalline cellulose and lactose mixed powder,
Vita hybrid tablets for the elderly, characterized in that the mixing ratio of the crystalline cellulose and lactose mixed powder is 1: 0.5 to 1: 0.7 by weight.
상기 코팅제는 히드록시프로필메틸셀룰로오스, 피마자유, 프로필렌글리콜, 폴리에틸렌글리콜, 포비돈, 탈크, 탄산칼슘, 카르나우바납, 이산화규소, 메타아크릴산 공중합체 및 산화티탄으로 이루어진 군에서 선택된 1종 이상으로 이루어지는 중장년층용 비타 하이브리드 정제.
The method of claim 1,
The coating agent is made of at least one member selected from the group consisting of hydroxypropyl methyl cellulose, castor oil, propylene glycol, polyethylene glycol, povidone, talc, calcium carbonate, carnauba lead, silicon dioxide, methacrylic acid copolymer and titanium oxide Vita hybrid tablets for.
상기 첨가제는 카르복시메틸셀룰로오스칼슘 0.5 내지 3%, 스테아린산마그네슘 0.5 내지 1.5%를 포함하는 중장년층용 비타 하이브리드 정제.
The method of claim 1,
The additive is a carboxymethyl cellulose calcium 0.5 to 3%, magnesium stearate magnesium vita hybrid tablets containing 0.5 to 1.5%.
중량%로, 비타민A 혼합제 0.5 내지 5%, 비타민B1 염산염 0.04 내지 0.4%, 비타민B2 0.03 내지 0.3%, 비타민B6 염산염 0.05 내지 0.5%, 비타민C 5 내지 15%, 비타민D3 혼합제 0.05 내지 0.5%, 비타민E 혼합제 7 내지 17%, 산화아연 0.5 내지 5%, 황산망간 0.1 내지 1%을 포함한 활성성분과, 결정셀룰로오스와 유당혼합분말 중에서 선택된 1종 또는 2종이 40 내지 60%를 포함한 부형제와, 기타 첨가제를 혼합기에 투입한 후 20 ~ 40분 동안 15 ~ 30 RPM으로 혼합하여 혼합물을 만드는 혼합 단계;
상기 혼합물을 자동 타정기를 이용하여 일정량으로 타정하는 타정 단계; 및
0.5 내지 5%의 코팅제를 주정알콜에 녹여서 코팅기제를 제조한 후 타정된 정제를 코팅기에서 코팅하는 코팅 단계;를 포함하는 중장년층용 비타 하이브리드 정제의 제조 방법.
A weighing step of weighing each raw material with an electronic balance;
By weight%, Vitamin A admixture 0.5 to 5%, Vitamin B1 hydrochloride 0.04 to 0.4%, Vitamin B2 0.03 to 0.3%, Vitamin B6 hydrochloride 0.05 to 0.5%, Vitamin C 5 to 15%, Vitamin D3 admixture 0.05 to 0.5%, Active ingredients including 7-17% of vitamin E blends, 0.5-5% of zinc oxide, 0.1-1% of manganese sulfate, excipients containing 40-60% of one or two selected from crystalline cellulose and lactose mixed powder, and the like. Adding an additive to the mixer and mixing the mixture at 15 to 30 RPM for 20 to 40 minutes to form a mixture;
A tableting step of tableting the mixture in a predetermined amount using an automatic tableting machine; And
A method of preparing a vita hybrid tablet for the elderly, comprising; a coating step of dissolving 0.5 to 5% of the coating agent in alcohol alcohol to prepare a coating base and then coating the tablets in a coating machine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120085121A KR20140017979A (en) | 2012-08-03 | 2012-08-03 | Vita hybrid tablet for middle aged adult and manufacturing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120085121A KR20140017979A (en) | 2012-08-03 | 2012-08-03 | Vita hybrid tablet for middle aged adult and manufacturing method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20140017979A true KR20140017979A (en) | 2014-02-12 |
Family
ID=50266319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120085121A KR20140017979A (en) | 2012-08-03 | 2012-08-03 | Vita hybrid tablet for middle aged adult and manufacturing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20140017979A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109198520A (en) * | 2018-10-13 | 2019-01-15 | 赤峰禾士营养食品科技有限公司 | A kind of composite nutrient with muscle-increasing function is good for flesh powder and preparation method thereof |
CN111012755A (en) * | 2020-01-09 | 2020-04-17 | 仁和堂药业有限公司 | Preparation process of vitamin B6 tablets |
-
2012
- 2012-08-03 KR KR1020120085121A patent/KR20140017979A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109198520A (en) * | 2018-10-13 | 2019-01-15 | 赤峰禾士营养食品科技有限公司 | A kind of composite nutrient with muscle-increasing function is good for flesh powder and preparation method thereof |
CN111012755A (en) * | 2020-01-09 | 2020-04-17 | 仁和堂药业有限公司 | Preparation process of vitamin B6 tablets |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050249821A1 (en) | Nutritional supplement for treatment of ocular diseases | |
JP2008509920A (en) | Composition and method for nutritional supplementation | |
RU2663017C2 (en) | Nutritional supplements for 50+ individuals for improving vitality, immunity, eye and bone health | |
KR20070111478A (en) | Compositions and methods for nutrition supplementation | |
JP2008508305A (en) | Compositions and methods for nutritional supplementation | |
CN107156832A (en) | It is a kind of to improve the health food of memory | |
KR20140017977A (en) | Vita hybrid tablet for senior and manufacturing method thereof | |
JP2011510922A (en) | Formulation containing calcium, magnesium, zinc and vitamin D3 for prevention and recovery of osteoporosis | |
KR100561286B1 (en) | Growth-promoting Composition Comprising Dried Yeast, Extracted Natural Substances and Nutrient Mixed Powder | |
CN101279089B (en) | Donkey-hide gelatin calcium composition and preparing process thereof | |
KR20140017979A (en) | Vita hybrid tablet for middle aged adult and manufacturing method thereof | |
KR20080008155A (en) | Nutritional composition comprising vitamins, minerals, or fermented natural substances especially necessary for koreans | |
CN105815770A (en) | Multivitamin/mineral formulation without side effects of large-dose nutritious supplement | |
JP2008237058A (en) | Dietary supplement | |
KR20140017976A (en) | Vita hybrid tablet for student and manufacturing method thereof | |
RU2327482C1 (en) | Composition and method of treatment of postintoxicational state and alcoholic abstinence syndrome-hangover (versions) | |
JP2007236308A (en) | Food composition | |
CN109090319A (en) | Newborn mineral salt pressed candy | |
CN107106603A (en) | Orally taken product | |
WO2022013581A1 (en) | Nutritional supplement, suitable for oral administration, comprising dihydromyricetin, choline and one or more vitamins with antioxidant activity, for use in the maintenance of normal liver function | |
CA2816207C (en) | Formulas comprising highly soluble elements and vitamin for the prevention and amelioration of osteoporosis | |
CN107510701B (en) | A kind of children mend the composition and its preparation method and application of iron and vitamin | |
CN101474304A (en) | Pharmaceutical composition for reducing blood sugar and blood fat | |
RU2275192C2 (en) | Vitamin-and-mineral complex | |
RU2377009C1 (en) | Weight-producing biologically active additive |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |